Archive

HIGHLIGHTS

 
LSP RECOMMENDS
BioCapital Europe 2017, organised by LSP
 
LSP COMPANY NEWS
LSP's portfolio company Atlas Genetics raises $ 35M in series D fundraising
 
LSP COMPANY NEWS
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
 
LSP RECOMMENDS
First full hospital roll-out of MedEye in the Netherlands
 
LSP COMPANY NEWS
Impacting patient lives with new diabetes drug approva
 
LSP COMPANY NEWS
Kiadis will start trial to treat children with severe blood disorder
 
LSP COMPANY NEWS
LSP announces $280 million final closing of life sciences venture fund
 
LSP RECOMMENDS
Wireless brain-spine connection to overcome paralysis
 
LSP COMPANY NEWS
LSP Venture Partner Hans Clevers gets prestigious Körber Award for his ground breaking research into stem cells and organoids, and appears in German prime time television news
 
LSP COMPANY NEWS
Rotation Medical, a prime example of innovation in healthcare to improve outcome and lower cost
 
LSP COMPANY NEWS
LSP’s portfolio company Merus announces global strategic collaboration with Incyte

2017


argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases
Differentiated antibody to address complement target  Represents latest collaboration to stem from the argenx Innovative Access Program  argenx granted option to license program after preclinical pro [...]
Merus Named BioCapital Europe 2017 Company of the Year
Award Recognizes Company’s Substantial Transformation and Breakthroughs Over Past 12 Months   UTRECHT, The Netherlands, March 16, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-o [...]
LSP invests in Orphazyme as part of a EUR 14 million Series B extension to further expand clinical programmes
Amsterdam, The Netherlands, March 15, 2017 - LSP portfolio company Orphazyme ApS announced today the completion of a EUR 14 million financing round. Together with the ALS Investment Fund, LSP joins the investor syndic [...]
argenx reports fourth quarter business update and full year 2016 financial results
Breda, the Netherlands / Ghent, Belgium, March 15, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea [...]
LSP takes part in Euronext Amsterdam gong ceremony
BioCapital Europe, an LSP healthcare conference, will take place for the 15th time in Amsterdam. Geraldine O’Keeffe, Partner at LSP and conference host, sounds the gong in recognition of the 15th anniversary of the [...]
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia
Anti-ApoC3 antibody developed as part of research collaboration on dyslipidemia- Represents latest collaboration to stem from the argenx's Innovative Access Program- argenx is eligible to receive a [...]


2017
2016
2015
2014
2013
2012
back to news overview

Archive

HIGHLIGHTS

 
LSP RECOMMENDS
BioCapital Europe 2017, organised by LSP
 
LSP COMPANY NEWS
LSP's portfolio company Atlas Genetics raises $ 35M in series D fundraising
 
LSP COMPANY NEWS
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
 
LSP RECOMMENDS
First full hospital roll-out of MedEye in the Netherlands
 
LSP COMPANY NEWS
Impacting patient lives with new diabetes drug approva
 
LSP COMPANY NEWS
Kiadis will start trial to treat children with severe blood disorder
 
LSP COMPANY NEWS
LSP announces $280 million final closing of life sciences venture fund
 
LSP RECOMMENDS
Wireless brain-spine connection to overcome paralysis
 
LSP COMPANY NEWS
LSP Venture Partner Hans Clevers gets prestigious Körber Award for his ground breaking research into stem cells and organoids, and appears in German prime time television news
 
LSP COMPANY NEWS
Rotation Medical, a prime example of innovation in healthcare to improve outcome and lower cost
 
LSP COMPANY NEWS
LSP’s portfolio company Merus announces global strategic collaboration with Incyte

$smarty.now|date_format:"%Y"


argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases
Differentiated antibody to address complement target  Represents latest collaboration to stem from the argenx Innovative Access Program  argenx granted option to license program after preclinical pro [...]
Merus Named BioCapital Europe 2017 Company of the Year
Award Recognizes Company’s Substantial Transformation and Breakthroughs Over Past 12 Months   UTRECHT, The Netherlands, March 16, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-o [...]
LSP invests in Orphazyme as part of a EUR 14 million Series B extension to further expand clinical programmes
Amsterdam, The Netherlands, March 15, 2017 - LSP portfolio company Orphazyme ApS announced today the completion of a EUR 14 million financing round. Together with the ALS Investment Fund, LSP joins the investor syndic [...]
argenx reports fourth quarter business update and full year 2016 financial results
Breda, the Netherlands / Ghent, Belgium, March 15, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea [...]
LSP takes part in Euronext Amsterdam gong ceremony
BioCapital Europe, an LSP healthcare conference, will take place for the 15th time in Amsterdam. Geraldine O’Keeffe, Partner at LSP and conference host, sounds the gong in recognition of the 15th anniversary of the [...]
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia
Anti-ApoC3 antibody developed as part of research collaboration on dyslipidemia- Represents latest collaboration to stem from the argenx's Innovative Access Program- argenx is eligible to receive a [...]


2017
2016
2015
2014
2013
2012
back to news overview